Agios Pharmaceuticals (LTS:0HB0) Other Income (Expense) : $1,095.24 Mil (TTM As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Agios Pharmaceuticals Other Income (Expense)?

Agios Pharmaceuticals's other income expense for the Agios Pharmaceuticals's pretax income for the three months ended in Mar. 2025 was $1.25 Mil. Its other income expense for the trailing twelve months (TTM) ended in Mar. 2025 was $1,095.24 Mil.

Agios Pharmaceuticals Other Income (Expense) Historical Data

The historical data trend for Agios Pharmaceuticals's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agios Pharmaceuticals Other Income (Expense) Chart

Agios Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Income (Expense)

Get a 7-Day Free Trial

21.07

144.45

6.06

1,095.62

Agios Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Other Income (Expense)	Get a 7-Day Free Trial															1.63	1.58	1,090.79	1.62	1.25

Agios Pharmaceuticals Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,095.24 Mil.

Agios Pharmaceuticals (LTS:0HB0) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Agios Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agios Pharmaceuticals Inc (LTS:0HB0) » Definitions » Other Income (Expense)

Comparable Companies

Traded in Other Exchanges

AGIO:USA 8AP:Germany 8AP:Germany

Address

88 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.agios.com

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Agios Pharmaceuticals Headlines

No Headlines